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a b s t r a c t
The separation-induced vocalization test in guinea pig pups is one of many that has been used to screen for
anxiolytic-like properties of drugs. The test is based on the cross-species phenomenon that infants emit distress
calls when placed in social isolation.
Here we report a systematic review and meta-analysis of pharmacological intervention in the separation-
induced vocalization test in guinea pig pups. Electronic databases were searched for original research articles,
yielding 32 studies that met inclusion criteria. We extracted data on pharmacological intervention, animal and
methodological characteristics, and study quality indicators.
Meta-analysis showed that the different drug classes in clinical use for the treatment of anxiety disorders,
have comparable effects on vocalization behaviour, irrespective of their mechanism of action. Of the experi-
mental drugs, nociception (NOP) receptor agonists proved very effective in this test. Analysis further indicated
that the commonly used read-outs total number and total duration of vocalizations are equally valid. With
regard to methodological characteristics, repeated testing of pups as well as selecting pups with moderate or
high levels of vocalization were associated with larger treatment effects. Finally, reporting of study
methodology, randomization and blinding was poor and Egger’s test for small study effects showed that pub-
lication bias likely occurred.
This review illustrates the value of systematic reviews and meta-analyses in improving translational value
and methodological aspects of animal models. It further shows the urgent need to implement existing
publication guidelines to maximize the output and impact of experimental animal studies.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).
1. Introduction
In the search for novel pharmacological treatment of anxiety
disorders, a wide range of animal models and tests has been used.
Anxiety tests may either be performed in naïve animals or in animals
in which aspects of the disease are modelled, e.g. by genetic modiﬁca-
tion or exposure to traumatizing stimuli. Furthermore, the read-outs
quantiﬁed in the test itself may be based on innate anxiety, condi-
tioned fear or conﬂict behaviour.
As of yet, it is unclear to what extent these approaches differ in
predicting potential clinical efﬁcacy and in detecting potential
drugable targets. Together with the still limited understanding of
the pathophysiology of anxiety disorders, this lack of knowledge
may have hampered the translation of preclinical ﬁndings to the
clinic (see Griebel and Holmes, 2013). In addition, limitations in
study quality and design of experimental animal studies may also
have contributed to this poor translation (Landis et al., 2012),
notwithstanding issues concerning the outcome of clinical trials,
such as high placebo responsiveness, patient selection and hetero-
geneity (Zimmerman et al., 2002).
As a ﬁrst step to objectively characterize drug sensitivity and
speciﬁcity of a particular anxiety test, we performed a systematic
review and meta-analysis on pharmacological interventions in the
separation-induced vocalization test in guinea pig pups and
characterized methodological factors that may affect test outcome.
In view of the concerns regarding study quality of experimental
animal studies (Landis et al., 2012), we also determined prevalence
of reporting of measures to reduce risk of bias and aimed to
characterize if biases in publication are likely to occur.
The separation-induced vocalization test in guinea pig pups is
based on the fact that pups emit distress calls when involuntarily
separated frommother and littermates (Herman and Panksepp, 1978;
Pettijohn, 1979a, 1979b). Narrative reviews indicate that, in contrast
to other tests, the guinea pig pup vocalization test is sensitive to a
broad range of antidepressants agents with anxiolytic properties
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(Sanchez, 2003; Borsini et al., 2002).This is an important observation
in light of the highly valued predictive validity of animal models
(Willner, 1984; Markou et al., 2009). Clinically, antidepressants are
prescribed more frequently, and are preferred over benzodiazepines
for the treatment of anxiety disorders (Baldwin et al., 2014; Chessick
et al., 2006), although the evidence to support this has recently been
questioned (Ofﬁdani et al., 2013; Rickels, 2013).
Besides detecting anxiolytic properties of antidepressant com-
pounds, the guinea pig pup vocalization test has some additional
valuable features. For certain neurotransmitter systems, human recep-
tor pharmacology is more akin to that of guinea pigs than that of rats
and mice, e.g. substance P (neurokinin (NK)1 receptors (Rigby et al.,
2005; Kramer et al., 1998; Lefﬂer et al., 2009) and the serotoninergic
system (5-HT1B, 5-HT1D receptors (Sipes and Geyer, 1996). In addition,
brain development in guinea pig pups is in a more advanced state
than that of rodents at birth (Clancy et al., 2007). Finally, the test
induces relatively low discomfort to the animals, is easy to perform,
and does not require special equipment, as guinea pig pups emit
mainly audible calls upon separation (400–20.000 Hz; Berryman,
1976), which can easily be quantiﬁed. Together, these observations
make this test interesting to further characterize pharmacologically
and methodologically.
As outcome measures for our evaluation of drug efﬁcacy in the
separation-induced vocalization test in guinea pig pups, we used the
total number and total duration of emitted vocalizations during social
isolation. In the meta-analysis, we only included drugs that were
hypothesized to reduce vocalization behaviour, whereas the systema-
tic review was not conﬁned to particular drug actions.
Literature suggests that both baseline levels of anxiety as well as
sensitivity to the anxiolytic-like action of drugs in rats and mice are
inﬂuenced by factors including strain (Griebel et al., 2000; Van Bogaert
et al., 2006), early life stress (Paris and Frye, 2011; Schopper et al.,
2011; Van Bogaert et al., 2006;Groenink et al., 2011) and environ-
mental enrichment (Hendriksen et al., 2012). To determine if these
factors affect drug efﬁcacy in guinea pigs as well, we included these
factors in our study. As behavioural studies indicate that age
(Hennessy and Ritchey, 1987; Arch-Tirado et al., 2000), duration of
social isolation (Monticelli et al., 2004), successive disturbances
(Hennessy et al., 2006; Arch-Tirado et al., 2000), test environment
(Hennessy and Ritchey, 1987) and presence of other guinea pigs in the
test room (Pettijohn, 1979a), may inﬂuence vocalization behaviour in
guinea pigs, we extracted information related to these factors as well.
In addition, we studied if selection of pups based on pre-test
vocalization levels, and repeated testing of animals impacted on study
precision and effect size.
Finally, with regard to study quality, we assessed whether rando-
mization, blinding and sample size calculations were reported and
performed, since these factors are key in reducing the risk of biased
results (Landis et al., 2012).
2. Material and methods
The systematic review was performed following a predeﬁned
protocol, the conditions of which are outlined below.
2.1. Literature search and study selection
Studies reporting drug treatment effects in separation-induced
vocalization tests in guinea pigs were identiﬁed by electronic
searching of Medline (via PubMed), Embase and Scopus, on
January 14th, 2014. The search strategy was broad: it was designed
to identify any study which measured vocalization behaviour in
guinea pigs, it was not restricted by pharmacological intervention
or language (for details see Table 1).
We applied the following criteria for in- and exclusion of peer-
reviewed, original research articles:
a. Only studies using guinea pigs were included. All strains of guinea
pigs were eligible, regardless of age and sex.
b. Only studies describing effect of drug treatment on separation-
induced vocalizations compared with control animals receiving
vehicle treatment were included.
c. Studies using a systemic route of drug administration were inclu-
ded. Studies using intra-cerebral or local infusion in speciﬁc brain
areas were excluded.
d. Studies describing drug effects in animals that had received
previous treatment, stress manipulations, lesions in the central
nervous system or other treatments aimed at altering baseline
levels of vocalizations were excluded.
e. Review articles not reporting original data were excluded.
f. If sufﬁcient information to compute effect sizes could not be
obtained from the article or from the primary or last author,
studies were excluded from the meta-analysis.
To identify articles meeting the inclusion criteria (see Section 2.2),
abstracts of retrieved articles were independently screened by two
investigators (MV, LG), using EROS 3.0 (Early Review Organizing
Software, Institute of Clinical Effectiveness and Health Policy, Buenos
Aires, Argentina). Discrepancies were solved by discussion among the
two investigators. In case information provided in the abstract was
insufﬁcient to decide upon in- or exclusion, both investigators
screened the full article, following the same procedure.
Table 1
Search terms used to identify relevant articles.
Data
base
Search string Hits
PubMed ((“Guinea pigs”[MeSH Terms] OR (“guinea”[All Fields] AND “pigs”[All Fields]) OR “guinea pigs”[All Fields] OR (“guinea”[All Fields] AND “pig”[All Fields])
OR “guinea pig”[All Fields]) OR (“guinea pigs”[MeSH Terms] OR (“guinea”[All Fields] AND “pigs”[All Fields]) OR “guinea pigs”[All Fields] OR “cavia”[All
Fields]) OR (“guinea pigs”[MeSH Terms] OR (“guinea”[All Fields] AND “pigs"[All Fields]) OR “guinea pigs"[All Fields] OR (“cavia"[All Fields] AND
“porcellus"[All Fields]) OR “cavia porcellus"[All Fields]) OR (“guinea pigs"[MeSH Terms] OR (“guinea”[All Fields] AND “pigs”[All Fields]) OR “guinea
pigs”[All Fields])) AND (Vocalization[All Fields] OR Vocalizations[All Fields] OR call[All Fields] OR calls[All Fields] OR (Distress[All Fields] AND vocalization
[All Fields]) OR (Distress[All Fields] AND vocalizations[All Fields]))
201
Embase (‘Guinea pig’/exp OR ‘guinea pig’ OR ‘cavia’/exp OR ‘cavia’ OR ‘cavia porcellus’/exp OR ‘cavia porcellus’ OR ‘guinea pigs’/exp OR ‘guinea pigs’) AND
(‘vocalization’/exp OR ‘vocalization’ OR ‘vocalizations’ OR ‘distress vocalization’ OR ‘distress vocalizations’ OR ‘call’ OR ‘calls’ OR ‘vocalization’ OR
‘vocalizations’)
208
Scopus (TITLE-ABS-KEY-AUTH(guinea pig) OR TITLE-ABS-KEY-AUTH(guinea pigs) OR TITLE-ABS-KEY-AUTH(cavia porcellus) OR TITLE-ABS-KEY-AUTH(cavia)) AND
(TITLE-ABS-KEY-AUTH(Vocalization) OR TITLE-ABS-KEY-AUTH(Vocalizations) OR TITLE-ABS-KEY-AUTH(Distress vocalization) OR TITLE-ABS-KEY-AUTH
(Distress vocalizations) OR TITLE-ABS-KEY-AUTH(Call) OR TITLE-ABS-KEY-AUTH(Calls) OR TITLE-ABS-KEY-AUTH(Vocalization) OR TITLE-ABS-KEY-AUTH
(Vocalizations))
255
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Table 2
Overview of pharmacological interventions in the isolation-induced vocalization test in guinea pig pups.
Paper Drug Route, ITI (min) Dose (mg/kg) Remark signiﬁcance IC50 (mg/kg) n
GABA-ergic system
Benzodiazepines
Molewijk et al. (1996) Alprazolam i.p., 30 0.3a/1a 0.32 8
Hodgson et al. (2007) CDP i.p., 30 1/3/10a NR NR
Varty et al. (2005) CDP i.p., 30 1/3/10a NR NR
Lamberty et al. (2004) CDP i.p., 30 5/10a NR Z6
Rupniak et al. (2000) CDP s.c., 30 0.3/3/10 sign NR 1,3 4–6
Kramer et al. (1998) Diazepam s.c., 30 0,3/1/3 sign NR NR 4–6
Molewijk et al. (1996) Diazepam i.p., 30 1a/3a/10a NR 8
Hudzik et al. (2003) Diazepam s.c., 15 3/5a/10a NR 4–8
Rupniak et al. (2000) Diazepam i.p., 30 0.1/0.3/1/3 sign NR 0.7 4–6
Benzodiazepine receptor inverse agonists
Molewijk et al. (1996) DMCM i.p., 30 1/3/10 Inactive NR 8
GABAA alpha1 sub-unit receptor agonists
Hudzik et al. (2003) Zolpidem s.c., 15 1/3a/10a NR 4–8
GABAA receptor agonists
Molewijk et al. (1996) Alcohol i.p., 30 100/300/1000a NR 8
Serotonergic system
Partial 5-HT1A receptor agonists
Molewijk et al. (1996) BMY 7378 i.p., 30 1/3/10 inactive NR 8
Borowsky et al. (2002) Buspirone i.p., 60 2a NR 10
Kramer et al. (1998) Buspirone s.c., 30 0,1/0,3/1/3 sign NR NR 4–6
Molewijk et al. (1996) Buspirone i.p., 30 0.3/1/3 Inactive NR 8
Rupniak et al. (2000) Buspirone s.c., 30 0.3/1/3 sign NR 0.45 4–6
Swanson et al. (2005) Buspirone p.o., 120 2a NR 10
5-HT1A receptor agonists
Molewijk et al. (1996) 8-OH-DPAT s.c., 30 0.1a/0.3a/1a NR 8
Molewijk et al. (1996) Flesinoxan i.p., 30 0.1/0.3a/1a NR 8
5-HT1B receptor antagonists
Zhang et al. (2011) AZD3783 mmol/kg s.c., NR 0.2a/0.6a/2a NR 12
Hudzik et al. (2003) GR 127935 s.c., 15 1/3/10a NR 4—8
Dawson et al. (2006) SB-616234-A i.p., 240 1/3a/10a NR 7
Hudzik et al., 2003 ar-a000002 s.c., 15 3/10/30a NR 4–8
5-HT1D receptor agonists
Molewijk et al. (1996) 5-CT i.p., 30 0.3a/1a/3a NR 8
5-HT2C receptor agonists
Molewijk et al. (1996) m-CPP i.p., 30 1/3/10 Inactive NR 8
5-HT3 receptor antagonists
Molewijk et al. (1996) Ondansetron i.p., 30 0.001/0.01/0.1 Inactive NR NR
SSRIs
Hudzik et al. (2003) Citalopram s.c., 15 0.3/1/3 Inactive NR 4–8
Molewijk et al. (1996) Clomipramine i.p., 30 1/3/10a NR 8
Dawson et al. (2006) Fluoxetine i.p., 30 1/3a/10a NR 6
Hudzik et al. (2003) Fluoxetine s.c., 15 1/3/10 Inactive NR 4–8
Rupniak et al. (2000) Fluoxetine i.p., 30 1/3/10/30 sign NR NR 4–6
Lamberty et al. (2004) Fluoxetine i.p., 30 5/10a NR Z6
Rupniak et al. (2000) Fluoxetine i.p., 30 1/3/10 sign NR 2.7 4–6
Steinberg et al. (2001) Fluoxetine i.p., 30 1/3a/10a NR 7–55
Chaki et al. (2005) Fluvoxamine s.c., 30 NRa NR
Molewijk et al. (1996) Fluvoxamine i.p., 30 3/10a/30a NR 8
Yokoyama et al. (2009) Fluvoxamine i.p., 30 30a
Millan et al. (2010) Paroxetine i.p., 30 0.16/2.5/10a NR 8–19
TCAs
Molewijk et al. (1996) Desipramine i.p., 30 1/3/10a NR 8
Yokoyama et al. (2009) Desipramine i.p., 30 30a NR 8–12
Kramer et al. (1998) Imipramine s.c., 30 3/10/30 sign NR NR 4–6
Lamberty et al. (2004) Imipramine i.p., 30 16/32a NR Z6
Rupniak et al. (2000) Imipramine s.c., 30 3/10/30 sign NR 5.4 4–6
Molewijk et al. (1996) Maprotiline i.p., 30 1/3/10a NR 8
SNRI’s
Rupniak et al. (2000) Venlafaxine s.c., 30 3/10/30 sign NR 8.2 4–6
MAO-A inhibitors
Molewijk et al. (1996) Clorgyline i.p., 30 1/3/10a NR 12
Kramer et al. (1998) Phenelzine s.c., 30 3/10/30 sign NR NR 4–6
Rupniak et al. (2000) Phenelzine s.c., 30 3/10/30 sign NR 8.6 4–6
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Table 2 (continued )
Paper Drug Route, ITI (min) Dose (mg/kg) Remark signiﬁcance IC50 (mg/kg) n
Dopaminergic system
Dopamine D2 receptor antagonist
Molewijk et al. (1996) Haloperidol i.p., 30 0.1/0.3/1 Inactive NR NR
Psychostimulants
Molewijk et al. (1996) d-Amphetamine i.p., 30 0.3/1/3 Inactive NR NR
Substance P/Neurokinin receptor system
NK 1 receptor antagonists
Millan et al. (2010) Aprepitant i.p., 30 0.63/10a/20a NR 5–32
Kramer et al. (1998) CGP49823 s.c., 30 1/30 Inactive NR 4–6
Rupniak et al. (2000) CGP49823 s.c., 30 1/30 Inactive NR 4–6
Harrison et al. (2001) Compound 3 p.o., 240 0.1/0.3/1 sign NR 0.2 4–6
Brocco et al. (2008) GR205,171 i.p., 30 0.01/0.04a/0.16a/0.63 NR 7–20
Rupniak et al. (2000) GR205,171 s.c., 30 1/3/10 sign NR 2.7 4–6
Brocco et al. (2008) GR226,206 i.p., 30 0.04/0.16/0.63/2.5 Inactive NR 5–24
Kramer et al. (1998) L-733,060 s.c., 30 1/3/10 sign NR NR 4–6
Rupniak et al. (2000) L-733,060 s.c., 30 1/3/10 sign NR 3.2 4–6
Rupniak et al. (2000) L-733,061 s.c., 30 3/10/30 Inactive NA 4–6
Kramer et al. (1998) L-760,735 s.c., 30 0.3/1/3 sign NR NR 4–6
Rupniak et al. (2000) L-796,325 s.c., 30 3/10/30 Inactive NA 4–6
Rupniak et al. (2000) LY-303870 s.c., 30 30 Inactive NA 4–6
Steinberg et al. (2002) SR240600 i.p., 30 1/3a/10a NR 7–55
Brocco et al. (2008) Vestipitant i.p., 30 0.16/2.5a/10a NR 7–16
Millan et al. (2010) S41744 i.p., 30 0.16a/0.63a/10a NR 11–27
Substance P release inhibitor
Hennessy et al. (2001) (7) E-6006 i.p., 30 3/10/30a/100a NR 12
Hennessy et al. (2001) (7) E-6006 i.p., 30 30 Inactive NR 16
Hennessy et al.,(2001) () E-6006 i.p., 30 30 Inactive NR 16
Hennessy et al. (2001) (þ) E-6006 i.p., 30 30a NR 16
NK2 receptor antagonists
Steinberg et al. (2001) SR 48965 i.p., 30 3/10 NR 7–55
Steinberg et al. (2001) SR 48968 i.p., 30 0.3/1/3a/10a NR 7–55
CRF systems
CRF1 receptor antagonists
Hodgson et al. (2007) CP154,526 i.p., 30 3/10a/30a NR NR (df)
CRF receptor antagonist
McInturf et al. (1996) D-Phe-CRF s.c., 0 50a NR 16
Hennessy et al. (1997) D-Phe-CRF s.c., 0 50a NR 12
Hennessy et al. (1997) D-Phe-CRF s.c., 0 15/50/150 Inactive NR 12
CRF receptor agonists
Becker et al. (1993) CRF s.c., 60 14 mga NR 7-8
Hennessy et al. (1991) CRF s.c., 30 14 mg Inactive NR 12
Schiml-Webb et al. (2009) CRF s.c., 0 10 mga NR
Hennessy et al. (1995) r/h CRF s.c., 30 7 mga NR 12
Hennessy et al. (1995) r/h CRF s.c., 60 7 mga/14 mga NR 12
Hennessy et al. (2011a) r/h CRF s.c., 60 10 mga NR 11–12
Vasopressin system
V1B receptor antagonists
Hodgson et al. (2007) SSR149415 i.p., 15 3/10/30a NR NR (df)
Central histaminergic system
Histamine H1 receptor antagonist
Lamberty et al. (2004) Chlorpheniramine i.p., 30 2/4/8/16 Inactive NR Z6
Lamberty et al. (2004) Hydroxyzine i.p., 30 4.3/8.1/14.3a NR Z6
Histamine H3 receptor agonist
Yokoyama et al. (2009) Immepip i.p., 15 3/10/30a NR 8–12
Lamberty et al. (2004) Immepip i.p., 30 5/10/20 Inactive NR Z6
Yokoyama et al. (2009) R-α-methylhistamine i.p., 15 3/10a/30a NR 8–12
Opioid system
m Opioid receptor agonists
Herman et al. (1978) Morphine s.c., 30 1a/2,5a/5a NR 23
Herman et al. (1978) Morphine s.c., 30 0.125a/0.25a/0.5a/0.75a NR 20
Herman et al. (1978) Morphine s.c., 30 1a/2.5a/5a NR 10
m Opioid receptor antagonists
Herman et al. (1978) Naloxone s.c., 30 1a NR 9
Herman et al. (1978) Naloxone s.c., 30 1 Inactive NR 10
Immune system
IL-10 receptor
Hennessy et al. (2011b) IL-10 i.p., 90 1 mg Inactive NR 11–12
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2.2. Data extraction
2.2.1. Study characteristics
The following study characteristics were retrieved from the
included articles by two independent investigators (MV, LG).
Discrepancies were solved by discussion among the two investi-
gators, or with a third investigator where necessary (BB).
2.2.1.1. Pharmacological intervention. Drug, mode of action of ad-
ministered drug, dose and route of drug administration, injection test
interval, vehicle control condition and treatment regimen (acute or
chronic dosing) were extracted.
2.2.1.2. Animals. Strain, age, bodyweight, and sex of animals used,
as well as origin of the pups (pregnant females from breeder, dam
and pups from breeder, own breeding colony). Regarding housing
conditions we also extracted data on housing (with mother, father,
siblings), bedding (grid, sawdust, other), and enrichment (shelter
yes/no, hay, extra vitamin C supplement).
2.2.1.3. Experimental conditions and study design. Test duration,
detection method (hand count or automated call quantiﬁcation), test
box characteristics, time of day relative to dark–light cycle, presence of
experimenter in test room, presence of other animals in test room. To
determine to what extent study design and repeated use of animals
may affect drug effects, we extracted information on total number of
tests per pup (once/two or three times/more than three times), study
design (full between/full within/repeatedly between/vehicle within),
number of days between test days and statistical analysis used
(parametric/non-parametric).
We initially aimed to extract data on the selection of pups by
assessing whether any pre-screening was performed (yes/no).
However, in an early phase of the extraction process we found
that the method of selection differed substantially between
studies. We therefore proceeded to record not only the presence
of pre-screening, but also the selection criteria used. If no state-
ment was made regarding selection of pups, this was interpreted
as no selection.
2.2.2. Outcome measures
For outcome data extraction, articles were randomly divided
between two investigators. Each investigator carried out initial data
extraction from the allocated articles and the second investigator
then checked all data entered by the ﬁrst investigator (MV, BB).
We collected data for the total number of emitted vocalizations and
the total duration of vocalizations. For each treatment and control
group we extracted the number of animals, mean and variance
(standard error of the mean or standard deviation). If outcome
measures were presented graphically, data were measured using
digital ruler software (Universal Desktop Ruler, AVPSoft.com). As
median and interquartile range data cannot readily be transferred to
a parametric scale, articles reporting such data could unfortunately not
be included in the meta-analysis (Schiml-Webb et al., 2009, 2006;
Hennessy et al., 2011b).
2.2.3. Study quality and risk of bias assessment
We assessed studies against the following quality indicators,
adapted from SYRCLE’s risk of bias tool (Hooijmans et al., 2014):
reporting of randomization at any level (y/n), random allocation to
intervention (y/unclear /n), reporting of blinding at any level (y/n),
concealment of allocation (y/unclear/n), adequate blinding of out-
come assessment (y/unclear/n), reporting of a sample size calcula-
tion (y/n), statement of a potential conﬂict of interest (y/n), and
sponsorship (non-proﬁt/(partly) proﬁt/unknown). Articles were
assessed independently by two investigators (MV, LG). Discrepan-
cies were solved by discussion among the two investigators.
2.3. Meta-analysis
We included data from all articles that aimed to identify anxiolytic-
like drug properties. In most articles, dose-response relationships were
reported (see Table 2). However, since inclusion of drug effects
obtained at suboptimal doses would interfere with interpretation of
the effect size estimates, we only included data for the most effective
dose tested (deﬁned as the dose inducing the largest difference in
Table 2 (continued )
Paper Drug Route, ITI (min) Dose (mg/kg) Remark signiﬁcance IC50 (mg/kg) n
CD4/TLR4/MD2 receptor complex
Hennessy et al. (2011b) LPS i.p., 90 0.075a NR 12
Melanocortin receptor agonist
Schiml-Webb et al. (2006) α-MSH i.p., 60 25 mg Inactive NR 10
Schiml-Webb et al. (2009) ɑ-MSH i.p., 0 25 mg Inactive NR 10
Neuropeptidergic systems -miscellaneous
BB1/BB2 receptor antagonist
Merali et al. (2006) PD 176252 i.p., 30 1/3/10a/30a NR 8
CCK2 receptor agonist
Molewijk et al. (1996) CI-988 i.p., 30 0.1/1/10 Inactive NR NR
GAL3 receptor antagonist
Swanson et al. (2005) SNAP 37889 p.o., 120 3a/10a/30a NR 10
MCH1 receptor antagonists
Borowsky et al. (2002) SNAP-7941 i.p., 60 3/10a/30a NR 10
Chaki et al. (2005) ATC0175 i.p., 60 1/3a/10a NR 8
NOP receptor agonists
Varty et al. (2005) Ro64-6198 i.p., 30 0.3/1a/3a NR NR (df)
Varty et al. (2008) SCH 221510 p.o., 120 0.3a/1a/3a NR 10-11
Lu et al. (2011) SCH 655842 p.o., 120 0.3/1a/3a NR 10
a Reported signiﬁcant dose relative to vehicle; ITI injection test interval; IC50 half maximal inhibitory concentration; n number of animals per condition; 5-HT serotonin,
BB bombesin; CDP chlordiazepoxide; CCK cholecystokinin; CRF corticotropin-releasing factor; GAL galanin; MAO mono-amine oxidase; MCH melanin-concentrating
hormone; MSH melanocyte stimulating hormone; NOP nociception; SNRI serotonin-noradrenaline reuptake inhibitor; SSRI selective serotonin reuptake inhibitor; TCA
tricyclic antidepressant; i.p. intraperitoneal; s.c. subcutaneous; p.o. oral; NR not reported; sign NR signiﬁcance not reported; df group size estimated based on reported
degrees of freedom. Gray line: insufﬁcient data, experiment not included in meta-analysis.
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outcome measure relative to vehicle control condition) in the meta-
analysis.
Data were analysed using Review Manager (version 5.2; Cop-
enhagen, The Nordic Cochrane Centre, The Cochrane Collaboration).
Data are presented as standardized difference in means and corre-
sponding 95% conﬁdence interval ((SMD [95% CI]): the mean of the
experimental group minus mean of the control group, divided by the
pooled SD of the two groups). The SMD was chosen because of
expected differences in test duration, which may vary between 5min
up to 3 h. Since vocalizations decrease over time, it is not possible to
average the number of calls e.g. per minute or per hour. Because of
this, the unit of measurement for our outcome measures is unlikely to
be uniform, and the SMD enables us to include different units of
measurement in one analysis for each outcome measure. Although
data were not independent for all studies, we treated them as such. To
account for expected heterogeneity, we used the random effect model
of DerSimonian and Laird. Subgroup analyses were performed to
investigate the inﬂuence of study variables on treatment effect, as well
as to explore possible causes for heterogeneity. Subgroups were
omitted from the analysis if they contained less than three experi-
ments, or were based on less than three articles. We pre-speciﬁed the
following subgroup variables:
a. Drug class (to be deﬁned separately for clinically active drugs
and experimental drugs).
b. Strain (laboratory code for Dunkin Hartley/Hartley as reported
in articles).
c. Gender (male/female/mixed).
d. Origin of the animals (colony/pregnant dam/dam with litter).
e. Age (young/mixed/old).
f. Test duration (5 min/10–15 min/430 min).
g. Selection on pre-screening vocalization level (no selection/
selection on moderate and high vocalization level/selection
on high vocalization level).
h. Repeated testing (once/two or three times/more than three times).
i. Design (within design/between design).
j. Detection (by hand/automated).
After extracting data on the drugs tested in the included stu-
dies, we further categorized the clinically effective drugs into four
categories: benzodiazapines, partial 5-HT1A agonists, selective
serotonin re-uptake inhibitors (SSRIs) and other anxiolytics/anti-
depressants. The experimental drugs were further categorized into
m-opioid receptor agonists, nociceptin (NOP) receptor agonists,
neurokinin (NK)1 receptor antagonists, substance P release inhibi-
tors, 5-HT subtype receptor targeting drugs, and other neuropeptide
and histamine targeting drugs.
Heterogeneity between studies was assessed using the I2 and T2
statistics. For the number of vocalizations, we corrected for multi-
ple testing of ﬁve subgroup variables by adjusting the signiﬁcance
level to 0.0102 using the Holm–Bonferroni correction. Publication
bias was investigated using funnel plotting and Egger regression.
3. Results
3.1. Study selection and search results
We identiﬁed 273 unique publications from the electronic search,
of which 241 publications were excluded (see Fig. 1). This review is
therefore based on data from 32 articles. We contacted ﬁrst and/or
last authors in an attempt to obtain missing data or study character-
istics. We received a response from ﬁve authors, two of which were
able to supply additional data.
3.2. Description of included studies
3.2.1. Pharmacological interventions
In Table 2, drug effects as reported in the included articles are sum-
marized. Drugs are sorted by neurotransmitter system and mechanism
of action. In total, 105 experiments were reported, involving either
registered anxiolytics/antidepressants with anxiolytic properties (37
experiments) or experimental compounds (68 experiments). In gen-
eral, ﬁndings were consistent between studies that tested the same
compound. With the exception of the NK1 receptor antagonist
GR205,171, the reported effective dose-ranges were comparable.
Effects of clinically active drugs were reported in fourteen of
the 32 articles, ﬁve of which tested more than one registered
anxiolytic/antidepressant. In total, sixteen different registered
anxiolytic/antidepressant were tested. SSRIs (ten experiments)
and benzodiazepines (nine experiments) were tested most often.
Paroxetine (six experiments), chlordiazepoxide (four experiments)
and diazepam (four experiments) were most frequently used as
representatives of these drug classes. Partial 5-HT1A receptor
agonists were tested six times. In twelve of the fourteen articles,
all reference compounds signiﬁcantly reduced vocalization beha-
viour. One study however, reported the absence of effect of partial
5-HT1A receptor agonists, whereas a wide range of other clinically
active drugs did reduce total number of vocalizations in that study
(Molewijk et al., 1996). Hudzik and co-workers reported that the
SSRIs citalopram and ﬂuoxetine had no effect in the vocalization
test, and that high doses of the benzodiazepine diazepam were
needed to reduce vocalization behaviour (Hudzik et al., 2003).
With regard to experimental drugs, 54 different compounds
were tested in 68 experiments. As shown in Table 2, a variety of
neurotransmitter systems was targeted. In total, the effects of 29
different mechanisms of action were investigated. Compounds
targeting the substance P/neurokinin system or the serotonin
system were tested most frequently.
In 79 of the 105 experiments, the compound under study
reduced the number and/or the total duration of vocalization,
Fig. 1. Flow chart of article selection process.
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which is indicative of an anxiolytic effect (Fig. 2A). In 26 experi-
ments the compound under study was inactive (including the
three registered anxiolytics/antidepressants mentioned above). In
most cases, this absence of a drug effect was anticipated by the
authors, as shown in Fig. 2A. These compounds were tested to
show e.g. stereo-selective activity (NK1 and NK2 receptor antago-
nists (Kramer et al., 1998; Steinberg et al., 2001; Rupniak et al.,
2000), to determine selectivity of the guinea pig pup vocalization
test (the psychostimulant d-amphetamine and the antipsychotic
haloperidol (Molewijk et al., 1996), or to study the role of the
immune system in passive behaviour, which is induced upon
prolonged social isolation (e.g. α-MSH, LPS and IL-10; Schiml-
Webb et al., 2006, 2009; Hennessy et al., 2011b).
In addition, the two anxiogenic compounds studied in this test, the
inverse benzodiazepine receptor agonist DMCM and the 5-HT2C
receptor agonist m-CPP were reported to be inactive (Molewijk et al.,
1996), as were the 5-HT3 receptor antagonist ondansetron, and the
cholecystokinin (CCK)2 receptor agonist CI-988 (Molewijk et al., 1996).
3.2.2. Animal characteristics
No article speciﬁed the laboratory code of the strain under study.
Instead, articles referred to the guinea pig strains using generic names.
The use of Dunkin–Hartley was reported in twelve articles, whereas
eight articles used Hartley guinea pigs. Twelve articles did not report
which guinea pig strain was used (see Table 3).
For most studies (twelve articles), pups were obtained by ordering
pregnant dams. If speciﬁed, these dams were around six weeks
pregnant (see Table 3; guinea pig gestation period is 60–73 days).
Alternatively, dams with litter (1–3 days old) were purchased from
suppliers (six articles), or pups were bred in a colony kept within the
own laboratory (ten articles). In four articles, origin of the pups was
not speciﬁed.
The age at which pups were tested varied from postnatal day
(PND) 4 to PND 42, and was often related to the study design.
Generally, when pups were tested once (between subjects design),
pups were not older than approximately 3 weeks, and the age-
range was limited to one week. When pups were tested repeat-
edly, or in a full within subjects-design (receiving all doses and
vehicle), they were up to 4 to 5 weeks old, and age within a study
ranged from two to four weeks (see Table 3 for details). Body
weight was only reported once (not shown).
As shown in Table 3, fourteen out of 32 articles stated that both
male and female pups were tested. Three of these articles actively
controlled for sex differences, either by allocating equal numbers
of both sexes to experimental groups (Hennessy et al., 1995, 2001),
or by including sex as a factor in the statistical design (Hennessy et al.,
1997).
Pups were always housed with mother and siblings, but the
number of nests and siblings within a cage varied, and was often
not well speciﬁed. Cages, bedding material, and presence of cage
enrichment were also poorly reported. Therefore, it was not possible to
categorize these variables in a meaningful way (data not shown).
3.2.3. Experimental characteristics and study design
The guinea pig infant separation calls have been classiﬁed as
“whistles”, which are mainly audible sounds (Berryman, 1976). The
ﬁrst studies indeed speciﬁed the type of calls quantiﬁed in the
guinea pig pup separation test, as high pitched calls (e.g. whistles).
This information however, is lacking frommost articles included in
this review.
Only two articles, both using automated quantiﬁcation of calls,
reported minimal length of a vocalization and minimal interval
between vocalization to qualify as two separate calls (Brocco et al.,
2008; Millan et al., 2010), whereas another paper used sono-
graphic recordings to identify calls with speciﬁed characteristics
(Molewijk et al., 1996). Quantiﬁcation by hand was most fre-
quently used (21 articles); automated quantiﬁcation was used in
three articles.
Test duration of the guinea pig pup vocalization test is typically
5 min (ﬁfteen articles), although 2 min test (one article) and test
durations from 12 to 15 min have also been performed (ﬁve
articles, Table 3). Articles using a considerable longer test duration
(30 min or more, ten articles), studied mechanisms underlying the
shift from active to passive coping behaviour during prolonged
social isolation.
In eighteen out of the 32 included articles, pups were selected
based on their vocalization behaviour during a pre-test. Selection
criteria used, ranged from 30 s to 200 s within 5 min, and from
200 to 600 calls within 5 min (see Table 3).
Depending on the study design (between subjects or within-
subjects study design), pups were tested once (nine articles), two
or three times (nine articles), or more frequently (eight articles;
see Table 4). Five articles did not report test frequency. In some
within-subjects studies, each pup received each dose and vehicle
treatment (nine articles), in four articles pups received one dose and
vehicle, in another four articles pups received two or three condi-
tions out of four or ﬁve possible conditions, including vehicle. Nine
articles used a between subjects design, with pups being tested only
once. Six articles did not (clearly) report the study design or
repeated use of pups.
We aimed to extract data on test variables including test box
(illumination), time of day relative to dark–light cycle, relocation
of pups or whole nest from facility to test room, presence of
experimenter in test room, and presence of other animals in
test room.
It proved difﬁcult however, to extract this information from
most articles (except for time of day relative to dark–light cycle).
Information was either missing (e.g. presence of other animals in
test room not reported in 50% of the articles), or reported in
general terms (e.g. ‘dimly lit’). It was therefore not possible to
structure these variables in a meaningful way.
3.3. Risk of bias and quality of reporting
As shown in Table 4, only three out of 32 included articles
(9.5%) reported that the study was randomized, without further
Fig. 2. Overview of experiments included in (A) the systematic review, and in (B) the meta-analysis.
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speciﬁcation of how the allocation sequence was generated and
applied. Blinding was reported in eight articles (25%), which
was further speciﬁed as blinding of observer in ﬁve of these
articles, and absence of blinding of observer in two articles. Only
two articles addressed incomplete outcome data, whereas no
article reported a sample size calculation. Five articles included a
conﬂict of interest statement, two of which reported a potential
conﬂict of interest. Consequently, all articles are considered to be
of poor quality.
3.4. Meta-analysis of outcome measures
Meta-analysis was performed on nineteen articles, reporting on
55 experimental comparisons. In the other thirteen articles (50
experiments), required data were missing (gray lines in Table 2,
Fig. 2B), or no anxiolytic-like drug properties were studied (see
Table 3, Fig. 2B).
Fifteen articles reported drug effects on the total number of
vocalizations, which included 43 vehicle-drug comparisons, using
Table 3
Animal characteristics and test characteristics of the separation-induced vocalization test in guinea pig pups.
Article Strain Origin animals Age
(days)
Sex Pre-screening
(selection criterion)
Test duration
(min)
Outcome
measure
Included in MA
exclusion/remark
Becker and Hennessy
(1993)
Hartley own colony 20-21 M/f
(¼)
NR [no] 30 Number N, different aim
Borowsky et al. (2002) NR NR 14 NR Yes (NR) 5 Number Y
Brocco et al. (2008) NR Pregnant dam (6
wk)
7–31 NR 430 s within 5 min 5 Number, duration Y
Chaki et al. (2005) NR Pregnant dam 7–28 NR 4200 s within 5 min 5 Number, duration Y
Dawson et al. (2006) Dunkin
Hartley
Pregnant dam 8–27 NR 4100 s within 15 min 15  , Duration Y
Harrison et al. (2001) NR NR NR NR NR [no] NR % Inhibition (NR) N, insufﬁcient data
Hennessy et al. (1991) Hartley Own colony 20–26 M/f
(¼)
NR [no] 30 Number N, different aim
Hennessy et al. (1995) Hartley own colony 20–21 m/f
(¼)
NR [no] 30 Number N, passive behaviour
Hennessy et al. (1997) Dunkin
Hartley
Own colony 20–26 M/f
(¼)
NR [no] 60 Number N, anxiogenic properties
Hennessy et al. (2001) Hartley Own colony 13–15 M/f
(¼)
NR [no] 30 Number Y
Hennessy et al. (2011a) NR Own colony 21–23 M/f
(¼)
No 180 Number N, passive behaviour
Hennessy et al. (2011b) NR Own colony 18–25 M/f
(¼)
NR [no] 60 Number N, medians, passive
behaviour
Herman et al. (1978) Dunkin
Hartley
Pregnant dam 7–17 M/f Yes (NR) 15 Number Y
Hodgson et al. (2007) Dunkin
Hartley
Pregnant dam 5–21 M/f NR [no] 5 Number Y (df)
Hudzik et al. (2003) Dunkin
Hartley
Pregnant dam (4
wk)
5–35 NR Yes (NR) 2 Number N, insufﬁcient data
Kramer et al. (1998) NR NR NR NR 4300 s within 15 min 15 % Inhibition
duration
N, insufﬁcient data
Lamberty et al. (2004) Dunkin
Hartley
Damþ litter 14 NR 4300 s within 12 min 12  , Duration Y
Lu et al. (2011) Dunkin
Hartley
Dam þ litter NR NR # 4200 within 5 min 5 Number Y
McInturf and Hennessy
(1996)
Hartley Own colony 20–26 M/f
(¼)
No 30 Number N, passive behaviour
Merali et al. (2006) Dunkin
Hartley
Dam þ litter NR NR # 4500 within 5 min 5 Number Y
Millan et al. (2010) Dunkin
Hartley
Pregnant dam (6
wk)
6–27 NR 430 s within 5 min 5 Number, duration Y
Molewijk et al. (1996) NR Pregnant dam 6–23 NR # 4200 within 5 min 5 Number Y
Rupniak et al. (2000) NR Pregnant dam 14–42 NR 4300 s within 15 min 15 % Inhibition (NR) N, insufﬁcient data
Schiml-Webb et al.
(2006)
NR Own colony 19–26 M/f
(¼)
NR [no] 180 Number N, passive behaviour
Schiml-Webb et al.
(2009)
NR Own colony 21–26 M/f
(¼)
NR [no] 60 Number N, medians; anxiogenic
Steinberg et al. (2001) Dunkin
Hartley
Damþ litter 12–24 NR 4120 s within 5 min 5  , Duration Y
Steinberg et al. (2002) Hartley NR 9–23 NR 4120 s within 5 min 5  , Duration Y
Swanson et al. (2005) Hartley Pregnant dam (6
wk)
14 NR NR [no] 5 Number Y
Varty et al. (2005) Hartley Damþ litter 6–20 M/f # 4200 within 5 min 5 Number Y (df)
Varty et al. (2008) Dunkin
Hartley
Damþ litter 6–20 M/f # 4200 within 5 min 5 Number Y
Yokoyama et al. (2009) NR Pregnant dam 7–8 NR No. of 4600 within
5 min
5 Number Y
Zhang et al. (2011) Dunkin
Hartley
Pregnant dam 4–25 NR Yes (NR) 5 Number Y
NR¼not reported; dam with litter ordered from breeder/pregnant dam from breeder; selection not reported, interpreted as NO selection; # number of calls; MA meta-
analysis; m/f both male and female pups ((¼) reported absence of sex difference); # total number of calls; duration total duration of calls; df: group size (n) estimated using
degrees of freedom; gray not included in meta-analysis. Insufﬁcient data e.g. data not reported/shown, number of animals tested was not reported, distortion not reported,
overlapping error bars, no data for vehicle condition. Different aim not studying anxiolytic drug properties.
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977 guinea pig pups in total. Seven articles reported drug effects
on the total duration of vocalizations. These included twenty
comparisons, using 762 pups. Drug effects on both the total
number and total duration of calls were analysed for eight
experiments from three articles (Brocco et al., 2008; Chaki et al.,
2005; Millan et al., 2010).
3.4.1. Pharmacological interventions
3.4.1.1. Total number of vocalizations. Results for drug effects on
total number of calls are summarized in Fig. 3. When pooling
data from all included experiments, drug treatment was
favoured over vehicle (SMD 1.99[2.33, 1.64], 15 articles,
43 experiments, 977 animals). Absolute and between study
heterogeneity for all studies combined were reasonably high
(T2¼0.97; I2¼77%).
Subgroup analysis showed that all drug classes (benzodiaze-
pines, partial 5-HT1A receptor agonists, SSRIs, m opioid receptor
agonists, NOP receptor agonists, NK1 receptor antagonists, and
substance P inhibitors) reduced the total number of vocalizations.
The anxiolytic effects of the included drug classes were well
within in the same range (see Table 5, Fig. 3).
For a number of drug classes, data were insufﬁcient to create
subgroups based on their mechanism of action (Table 5).
For visualization in the forest plot, these remaining com-
pounds were therefore grouped (but not pooled), based on their
clinical effect (anxiolytics/antidepressants miscellaneous) or neu-
rotransmitter system targeted (5-HT subtype receptor miscella-
neous, neuropeptides and histamine miscellaneous, experimental
miscellaneous).
A subgroup analysis comparing three classes of clinically active
anxiolytics (benzodiazepines, partial 5-HT1A receptor agonists and
SSRIs), showed that the effect of these drug classes on total
number of vocalizations did not differ (Fig. 3, Table 5). Overall
and between study heterogeneity in the SSRI subgroup was low
(I2¼ 0%, T2¼0.0), compared to the other two classes (I2¼ 56%,
T2¼0.48 and I2¼ 75%, T2¼0.96 for benzodiazepines and partial 5-
HT1A receptor agonists, respectively).
Out of all experimental drug classes studied, NOP receptor
agonists appeared to have the largest effect (SMD 4.39 [5.41,
3.37], three articles, three experiments, 60 animals). Heteroge-
neity was low in this subgroup (τ2¼0 and I2 0%), and the reduction
in vocalizations after treatment with NOP receptor agonists was
large, when compared to benzodiazepines, partial 5-HT1A receptor
Table 4
Study characteristics and risk of bias assessment scores.
Study characteristics Study quality
Article Quantiﬁcation
method
Number of
tests
per pup
Design Randomization
reported
Blinding
reported
Sample size
calculation
Conﬂict of interest
statement
Becker et al. (1993) Hand 1 Full between NR NR NR NR
Borowsky et al. (2002) NR 2 Repeatedly,
between
NR NR NR Y
Brocco et al. (2008) Automated 5 Full within Y NR NR Y (no conﬂict)
Chaki et al. (2005) Recorded 5 Full within NR NR NR NR
Dawson et al. (2006) Automated 4 Full within Y Y NR NR
Harrison et al. (2001) NR NR NR NR NR NR NR
Hennessy et al. (1991) Hand 1 Full between NR NR NR NR
Hennessy et al. (1995) Hand 1 Full between NR NR NR NR
Hennessy et al. (1997) Hand 2 Vehicle within NR NR NR NR
Hennessy et al. (2001) Hand 1 Full between NR NR NR NR
Hennessy et al. (2011a) Hand 1 Full between NR Y (not blinded) NR Y (no conﬂict)
Hennessy et al. (2011b) Hand 1 Full between NR NR NR NR
Herman and Panksepp
(1978)
Hand 5 Full within NR NR NR NR
Hodgson et al. (2007) Hand NR NR NR Y NR NR
Hudzik et al. (2003) Hand 4 Full within NR NR NR NR
Kramer et al. (1998) NR NR NR NR NR NR NR
Lamberty et al. (2004) Hand 1 Full between Y NR NR NR
Lu et al. (2011) Hand NR NR NR Y NR NR
McInturf and Hennessy
(1996)
Hand 2 Full within NR NR NR NR
Merali et al. (2006) Recorded 1 Full between NR NR NR NR
Millan et al. (2010) Automated 5 Full within NR NR NR Y
Molewijk et al. (1996) Recorded 5 Full within NR NR NR NR
Rupniak et al.,(2000) NR 6 Within NR NR NR NR
Schiml-Webb et al.
(2006)
Hand 3 Vehicle within NR Y (not blinded) NR NR
Schiml-Webb et al.
(2009)
Hand 2 Full within NR NR NR NR
Steinberg et al. (2001) Hand 3 Vehicle within NR NR NR NR
Steinberg et al. (2002) Hand 3 Vehicle within NR NR NR NR
Swanson et al. (2005) NR 2 Repeatedly,
between
NR Y NR Y (no conﬂict)
Varty et al. (2005) Hand 6 Between NR Y NR NR
Varty et al. (2008) Hand 3 Repeatedly,
between
NR NR NR NR
Yokoyama et al. (2009) Hand 1 Full between NR Y NR NR
Zhang et al. (2011) Hand NR NR NR NR NR NR
NR not reported; Y yes; gray not included in meta-analysis.
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Fig. 3. Forest plot of all included studies on the effect of pharmacological intervention on total number of calls, sorted by subgroups and divided into I. clinically active and II.
experimental drug categories (upper and lower panel). The forest plot displays the SMD, 95% CI and relative weight of the individual studies. Experiments are labelled by
author, publication year, compound and dose included in the meta-analysis.
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agonists and SSRIs (ΔSMD respectively 2.66[1.29, 4.03], 2.86[1.22,
4.50] and 2.13 [0.99, 3.27]).
3.4.1.2. Total duration of vocalizations. Pooling of all available
experiments showed that pharmacological intervention reduced
the total duration of vocalizations relative to vehicle treatment
(SMD 1.70, [2.14, 1.26], 20 experiments, 762 animals). Total
and between study heterogeneity were reasonably high (I2¼81%;
T2¼0.69; Fig. 4).
Subgroup analysis for duration of vocalizations were performed
for SSRIs and NK1 receptor antagonists. For a number of other drug
classes, data were insufﬁcient to create subgroups based on their
mechanism of action (Table 6). For visualization in the forest plot,
these remaining compounds were therefore grouped (but not
pooled) in two categories (anxiolytics/antidepressants miscella-
neous and experimental miscellaneous).
Total duration of vocalizations was reduced for both SSRIs and
NK1 receptor antagonists (Fig. 4), and effect sizes did not differ
between these subgroups (ΔSMD not signiﬁcant).
Heterogeneity was modest in both groups (I2¼42% and 66%,
and T2¼0.20 and 0.31, respectively).
3.4.2. Meta-analysis of methodological characteristics
3.4.2.1. Total number of vocalizations. Since only generic names were
used to indicate the guinea pig strain studied, stain differences were
not analyzed.
Subgroup analysis indicated an overall effect of the variable origin
of pups on treatment efﬁcacy (see Table 5). Between-subgroup
analysis, could only be performed for the subgroups pregnant dam
and dam with litter. In both these subgroups, pharmacological treat-
ment was favoured over vehicle and comparable effect sizes were
obtained.
To determine the impact of age on drug effects on vocalization
behaviour, experiments were categorized in three subgroups: young
(PND 7–PND 17), mixed age (PND 4–PND 31) and old (PND18–26;
insufﬁcient data). Subgroup analysis showed an overall effect of the
variable age on treatment efﬁcacy. However, no difference bet-
ween the young and the mixed age groups was observed (Table 5).
For the variable test duration, subgroups were too small to perform
reliable analysis.
To study the effect of animal selection on effect size
and precision of test results, experiments were categorized in
three subgroups: no selection, selection on moderate to high
vocalization level (total duration at least 30 s within 5 min, or at
least 200 calls within 5 min), and selection on high vocalization
level (at least 120 s within 5 min, or at least 500 calls within
5 min). In all subgroups, pharmcological treatment was favoured
over vehicle (Table 5). Subgroup analysis showed an overall effect
of the variable selection on treatment efﬁcacy. Comparisons
between subgroups revealed that treatment effect in experiments
without selection was signiﬁcantly smaller compared to the
moderate/high (ΔSMD 1.15[0.48, 1.82] and high subgroups
(ΔSMD 0.78[0.10, 1.46]. The effect of pharmacological treatment
did not differ between the moderate/high and high subgroups
(ΔSMD 0.37[0.40, 1.14]).
To determine the effect of repeated testing on treatment
effects, we compared three subgroups, based on the total number
of tests a pup was exposed to: one test, two or three tests or more
than three tests. Overall, the variable repeated testing had a
signiﬁcant effect on treatment efﬁcacy. Pharmacological treat-
ment reduced the total number of calls in all subgroups
(Table 5). Between-subgroup comparisons indicated that the effect
of treatment was signiﬁcantly smaller in pups tested once (SMD
1.16 [1.61, 0.70]) than in pups tested two to three times
Fig. 4. Forest plot of all included studies on the effect of pharmacological intervention on total duration of calls. Drugs are sorted by subgroups and divided into I. clinically
active and II. experimental drug categories (upper and lower panel). The forest plot displays the SMD, 95% CI and relative weight of the individual studies. Studies are labelled
by author, publication year, compound and dose included in meta-analysis.
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(SMD 2.41 [3.32, 1.50]; ΔSMD 1.25 [0.23, 2.27]) and pups
tested more than three times (SMD 2.35 [2.88, 1.81], ΔSMD
1.19 [0.48, 1.89]).
3.4.2.2. Total duration of vocalizations. No subgroup analyses were
performed for total duration of vocalizations, because of insufﬁcient
numbers of experiments and/or articles, except for the variable
selection of pups (see Table 6). The effect of pharmacological
treatment did not differ between the moderate/high and high
selection subgroups (SMD not signiﬁcant). There were insufﬁcient
data to compare these subgroups with the no-selection subgroup.
3.4.2.3. Comparison of outcome measures. When pooling data from
all nineteen included articles, the two outcome measures did not
differ in the effects induced by the pharmacological interventions
(total number of calls SMD 1.99, [2.33, 1.64], 43 experiments,
977 animals (Fig. 3) versus total duration SMD 1.70, 95% CI [2.14,
1.26], 20 experiments, 762 animals (Fig. 4). Distortion (CI), absolute
heterogeneity (τ2¼0.97 and 0.69, respectively), and heterogeneity
between studies (I2¼77% and 81%, respectively) did also not differ
between the two outcome measures.
Furthermore, a strong, signiﬁcant correlation was found between
the total number of calls and the total duration of calls (Spearman’s
Rho¼0.83, Fig. 5).
3.5. Publication bias
Visual inspection of a funnel plot (Fig. 6) for the total number of
vocalizations indicates that the plot is asymmetrical, due to an
underrepresentation of imprecise studies reporting a neutral or
negative effect. This ﬁnding indicates the possible presence of
publication bias. These ﬁndings are in line with the results of
Egger’s test for small study effects, which indicates that plot
asymmetry is present (Po0.0001). Data were insufﬁcient to per-
form a similar analysis for the total duration of calls.
Table 5
Subgroup statistics for total number of vocalizations.
Subgroup # Articles # Experiments # Animals SMD[CI]
All studies 15 43 977 1.99 [2.33, 1.64]
Drug class
Registered
Test for subgroup differences NS
10 13 247 1.80 [2.29, 1.30]
Benzodiazepines 3 4 68 1.73 [2.64, 0.82]
5-HT1A partial agonists 3 4 72 1.53 [2.81, 0.25]
SSRIs 4 5 107 2.26 [2.78, 1.75]
Anxiolytics/antidepressants miscellaneous 2 3 60 Not pooled
Experimental
Test for subgroup differences NA
μ Opioid receptor agonists 1 3 106 4.13 [6.61, 1.65]
NOP receptor agonist 3 3 60 4.39 [5.41, 3.37]
NK1 receptor antagonists 2 5 152 1.88 [2.53, 1.22]
Substance P release inhibitors 1 4 120 0.65 [1.05, 0.26]
5-HT subtype receptor miscellaneous 2 4 69 Not pooled
Neuropeptides and histamine miscellaneous 6 8 163 Not pooled
Origin
Test for subgroup differences Po0.00001
Colony 1 4 120 0.65 [1.05, 0.26]
Pregnant dam 9 32 720 2.06 [2.44, 1.69]
Dam with litter 4 5 97 2.95 [4.61, 1.29]
Not reported 1 2 40 1.99 [2.78, 1.20]
Age
Test for subgroup differences Po0.00001
Young o17 days 5 15 402 1.93 [2.55, 1.32]
Mixed (4–31 days) 8 26 538 2.00 [2.43, 1.58]
Old 418–26 days 0 0 0 NA
Not reported 2 2 37 2.34 [5.02, 0.34]
Test duration
Test for subgroup differences NA
5 min 13 36 751 1.96 [2.28, 1.64]
10–15 min 1 3 106 4.13 [6.61, 1.65]
430 min 1 4 120 0.65 [1.05, 0.26]
Selection
Test for subgroup differences Po0.00001
None 3 9 218 1.06 [1.45, 0.66]
Moderate/high vocalization 6 21 444 2.21 [2.76, 1.67]
High vocalization 3 7 145 1.84 [2.39, 1.29]
Not reported 3 6 170 2.91 [4.11, 1.70]
Repeated testing
Test for subgroup differences Po0.00001
Once 3 9 233 1.16 [1.61, 0.70]
2-3 times 3 5 102 2.41 [3.32, 1.50]
4 or more times 6 24 540 2.35 [2.88, 1.81]
Not reported 3 5 102 1.63 [2.34, 0.92]
NA not applicable; NS not signiﬁcant; # number; SMD standardized mean difference; CI conﬁdence interval; Subgroups consisting of less than three experiments and/or less
than three articles were excluded from between subgroup analyses.
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3.6. Sensitivity analysis
We performed a number of sensitivity analyses related to the
classiﬁcation and grouping of the experiments based on the drug
properties. First, we excluded the experiment studying BMY7378 from
the subgroup partial 5-HT1A receptor agonists, since BMY7378, unlike
buspirone, is not a registered, clinically active partial 5-HT1A receptor
agonist. Second, we excluded an experiment studying GR226,206,
considered an inactive enantiomer, from the subgroup NK1 receptor
antagonists. Thirdly, we excluded an experiment studying S41744, a
dual NK1 receptor antagonist and serotonin re-uptake inhibitor from
the NK1 receptor antagonist subgroup. Exclusion of either GR226,206
or S41744 reduced heterogeneity in the NK1 receptor antagonist
subgroup for both the number and duration of calls. None of the
sensitivity analyses had any signiﬁcant effects on the direction or
magnitude of the effect for either outcome measure.
4. Discussion
4.1. Pharmacological intervention
In this systematic review and meta-analysis, we studied the
effect of registered anxiolytics and antidepressants with anxiolytic
properties in the separation-induced vocalization test in guinea
pig pups, examined potential differences between these classes,
and assessed the effect of experimental drug classes in this test.
We found that SSRIs, benzodiazepines and partial 5-HT1A receptor
agonists all reduced vocalization behaviour to a similar extent. Of
the experimental compounds tested, NOP receptor agonists mark-
edly reduced the number of vocalizations in guinea pig pups. The
effect of this drug class was signiﬁcantly stronger than that of
SSRIs, benzodiazepines and partial 5-HT1A receptor agonist.
Besides SSRIs and partial 5-HT1A receptor agonists, several
other serotonergic drug classes have been studied for putative
anxiolytic and/or antidepressant actions. The 5-HT1A receptor
agonists ﬂesinoxan and 8-OH-DPAT, the 5-HT1B receptor antago-
nists AZD3783 and SB-616234-A, and the mixed 5-HT1D agonist
5-CT have been tested in the guinea pig vocalization test (Dawson
et al., 2006; Hudzik et al., 2003; Zhang et al., 2011). The ﬁndings in
the current review do not support the suggestion that vocalization
tests are particular sensitive to serotonergic compounds (Sanchez,
2003). Effects of these serotonergic compounds appeared low to
moderate. 5-CT appeared to have the largest effect on vocalization
behaviour. The mechanism of action of 5-CT is broad and includes
agonist action at 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2, 5-HT3, 5-HT5A and
5-HT7 receptors (Yamada et al., 1998). Since no comparable com-
pounds were tested, this large effect cannot readily be interpreted.
Meta-analysis showed that NOP receptor agonists strongly
reduced the total number of vocalizations. Although all three
Table 6
Subgroup statistics for total duration of vocalizations.
Subgroup # Articles # Experiments # Animals SMD[CI]
All studies 7 20 762 1.70 [2.14, 1.26]
Drug class
Registered
Test for subgroup differences NA
SSRIs 5 5 181 2.14 [2.76, 1.51]
Anxiolytics/antidepressants miscellaneous 1 3 36 Not pooled
Experimental
Test for subgroup differences NA
NK1 receptor antagonists 3 6 271 1.52 [2.08, 0.96]
Experimental miscellaneous 4 6 274 Not pooled
Origin
Test for subgroup differences NA
Colony 0 0 0 NA
Pregnant dam 3 10 250 1.79 [2.37, 1.21]
Dam with litter 2 9 402 1.64 [2.44, 0.83]
Not reported 1 1 110 1.46 [1.88, 1.03]
Age
Test for subgroup differences NA
Young o17 days 1 6 72 1.66 [2.43, 0.89]
Mixed (4-31 days) 6 14 690 1.70 [2.22, 1.18]
Old 418–26 days 0 0 0 NA
Test duration
Test for subgroup differences NA
5 min 5 12 664 1.63 [2.17, 1.09]
10–15 min 2 8 98 1.84 [2.61, 1.06]
4 30 min 0 0 0 NA
Selection
Test for subgroup differences NS
None 0 0 0 NA
Moderate/high vocalization 3 8 218 1.67 [2.31, 1.03]
High vocalization 4 12 544 1.71 [2.32, 1.11]
Repeated testing
Test for subgroup differences NA
Once 1 6 72 1.66 [2.43, 0.89]
2–3 times 2 4 440 1.48 [2.47, 0.49]
4 or more times 4 10 250 1.79 [2.37, 1.21]
NA not applicable; NS not signiﬁcant; # number; SMD standardized mean difference; CI conﬁdence interval; Subgroups consisting of less than three experiments and/or less
than three articles were excluded from between subgroup analyses.
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studies were performed in the same research laboratory, the fact
that modest to low effects were reported for the benzodiazepine
chlordiazepoxide, makes it unlikely that the large effects of NOP
receptor agonists are solely due to speciﬁc testing conditions
(Varty et al., 2005).
NOP receptors, also known as opioid like receptors, or nocicep-
tion opioid receptors, are located throughout the human and
rodent brain, including the cortex, extended amygdala, periaque-
ductal grey, raphe nuclei and hypothalamus (Mallimo and
Kusnecov, 2013). The receptor shares 60% homology with opioid
receptors, but neither the NOP receptor agonists tested, nor the
endogenous ligand orphanin FQ/nociception [OFQ/N] bind to
classic opioid receptors (Varty et al., 2005, 2008; Lu et al., 2011).
Likewise, opioid receptor ligands do not bind to NOP receptors.
Several disease states have been associated with changes in
nociception levels, including anxiety and addiction, but potential
therapeutic beneﬁt of NOP receptor ligands has not yet been
assessed in humans (Witkin et al., 2014).
Tachykinins, including substance P and neurokinin A, and NK1
and NK2 receptors are implicated in the regulation of stress related
behaviour and the aetiology of anxio-depressive states (McCabe
et al., 2009; Ebner et al., 2009; Millan et al., 2010; Harrison et al.,
2001; Steinberg et al., 2002). In the isolation-induced vocalization
test, three different drug classes targeting the neurokinin system
were tested: NK1 receptor antagonists, NK2 receptor antagonists
and substance P release inhibitors. Meta-analysis showed that all
three drug classes reduced vocalization behaviour. Clinical trials of
selective NK1 antagonists on social anxiety and depression how-
ever, have yielded disappointing results (Millan, 2006; Poma et al.,
2014)).
Both postsynaptic histamine H1 and presynaptic H3 receptors are
thought to modulate emotion and stress regulation (Lamberty and
Gower, 2004; Leurs et al., 2005). Although the histamine H1 receptor
antagonist, hydroxyzine is generally considered a weak anxiolytic,
recent reviews concluded that hydroxyzine was equally effective to
other anxiolytic agents, like benzodiazepines and buspirone (Huh
et al., 2011; Guaiana et al., 2010). In the guinea pig pup vocalization
test, hydroxyzine reduced total duration of calls, whereas the proto-
typic H1 receptor antagonist chlorpheniramine was inactive. The
authors pointed out that additional non-histaminergic effects are
probably involved in the tranquilizing action of hydroxyzine
(Lamberty and Gower, 2004). The two histamine H3 receptor agonists
tested, showed mixed results (Yokoyama et al., 2009; Lamberty and
Gower, 2004). We could not further analyse these effects, since
different outcome measures were used.
Morphine was one of the ﬁrst compounds tested in the guinea pig
pup vocalization test and proved rather effective in reducing the total
number of calls (Herman and Panksepp, 1978), also relative to
registered anxiolytics/antidepressants. Clearly, the actions of the
opioid receptor agonist morphine are not comparable to those of
standard anxiolytics. Importantly, though, the guinea pig pup voca-
lization test was originally studied in relation to development of
social bonding and attachment (Herman and Panksepp, 1978; Nelson
and Panksepp, 1998). The effects of morphine and the opioid receptor
antagonist naloxone on vocalization behaviour in guinea pig pups
indicate that endogenous endorphins also modulate emotional
behaviour associated with social isolation and attachment (Herman
and Panksepp, 1981; Nelson and Panksepp, 1998).
The modest reduction of isolation calls following treatment
with the CRF1 receptor antagonist CP154,526 (Hodgson et al.,
2007), is interesting in light of the extensive work of Hennessy
and co-workers regarding social isolation-induced behaviour in
guinea pig pups. Guinea pig pups exhibit an initial active coping
style, characterized primarily by vocalizing, which is then followed
by a stage of passive behaviour in which pups display a crouched
posture and extensive pilo-erection (Hennessy et al., 1995;
McInturf and Hennessy, 1996). The work of Hennessy and co-
workers indicates that subcutaneously administered CRF may
accelerate the onset of passive behaviours, thereby reducing
vocalization behaviour (Hennessy et al., 1991, 1997; Schiml-
Webb et al., 2009). This is an important observation as it implies
that a reduction in vocalization behaviour does not necessarily
reﬂect a reduction in anxiety.
Apart from the above mentioned drugs, several other compounds
have been tested: a bombesin BB1/BB2 receptor antagonist, a galanin
GAL3 antagonist, MCH1 receptor antagonists, and a vasopressin V1B
receptor antagonist. These compounds all target neuropeptidergic
systems that have been associated with emotional regulation
(Holmes et al., 2003; Merali et al., 2006; Borowsky et al., 2002;
Chaki et al., 2005; Swanson et al., 2005).These compounds were,
however, tested only once and could not further be categorized for
subgroup analysis. At global glance, most compounds had low to
moderate effects on vocalization behaviour. It remains to be seen
how these effects hold upon further testing, since publication bias
may partly account for the positive effects.
4.1.1 Sensitivity and speciﬁcity of the separation-induced voca-
lization test in guinea pig pups Based on the current review, we
conclude that the sensitivity of the separation-induced vocaliza-
tion test in guinea pig pups for registered anxiolytics is high. All
registered anxiolytics/antidepressants with anxiolytic properties
were found active in the test. Almost all experimental compounds
tested however, were also found active. This could be interpreted
Fig. 6. Funnel plot for the outcome measure total number of vocalizations.
Fig. 5. Scatter plot of group mean values of total duration versus total number of
calls obtained from dose-response studies reported in (Millan et al., 2010; Brocco
et al., 2008; Chaki et al., 2005). Data points include both vehicle (open circles, n¼7)
and experimental conditions (closed circles, n¼24).
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in two ways. Due to publication bias, neutral and negative ﬁndings
could be under represented. Alternatively, the translational value of
the test may be moderate. Selective NK1 receptor antagonists for
instance, had an anxiolytic effect in this test, but proved disappointing
in clinical studies (Millan, 2006). There were however, insufﬁcient data
to reliably determine pharmacological sensitivity and speciﬁcity of the
test. Much to our surprise, even with regard to positive reference
compounds, evidence was relatively scarce. Incidental studies, all from
the same research laboratory, suggest that the test does have a certain
level of speciﬁcity. The stimulant, d-amphetamine, and the antipsy-
chotic haloperidol were rightly found inactive, as were the experi-
mental anxiolytics ondansetron, a 5-HT3 receptor antagonist, and CI-
988, a CCK2 receptor antagonist (Harro, 2006; Molewijk et al., 1996).
On the other hand, the 5-HT1A receptor agonist ﬂesinoxan proved a
false positive in the test (van Vliet et al., 1996).
Incidental studies further suggest that the test does not detect
anxiogenic drug properties
(Molewijk et al., 1996), although this may well depend on the
basal level of vocalization (see e.g. Groenink et al., 1996).
4.2. Methodological characteristics
The way in which the separation-induced vocalization test is
performed, differs considerable between studies. Using subgroup
analysis, we identiﬁed two test conditions associated with larger
effect sizes upon pharmacological intervention: selection of animals
with a moderate to high pre-test vocalization level and repeated
testing of pups. Based on the data currently available, we conclude
that origin and age of pups do not inﬂuence effect size.
Subgroup analysis showed that in studies that included all
pups, irrespective of vocalization behaviour, smaller effects were
found than those applying a selection criterion based on pre-test
vocalization levels. Furthermore, with regard to effect size and
precision, selection of pups with a high pre-test vocalization level
(at least 120 s or 500 calls within 5 min) has no added value over
selection of animals with a moderate to high vocalization level.
Rupniak and co-workers (Rupniak et al., 2000) reported that over
50% of the pups did not qualify when using a criterion of over
300 s vocalization within 15 min). In case of selecting moderate to
high vocalizers (430 s within 5 min), approximately 7% of the
pups was excluded from the experiment (information from
authors (Brocco et al., 2008; Millan et al., 2010)). Thus, applying
the moderate to high selection criterion could considerably reduce
the number of animals discarded, without affecting effect size.
Subgroup analysis of the variable repeated testing showed that the
effect of pharmacological treatment on the total number of calls was
signiﬁcantly smaller in pups tested once than in pups tested two or
three times and pups tested more than three times. This ﬁnding
suggest that repeated testing of pups is preferred for this test, since it
appears to generate a larger effect size, and also reduces the total
number of animals needed, relative to a between-subjects design,
without reducing precision. Of note, in this analysis we did not take
into account the additional reduction in variance generally obtained by
applying a within subjects design, since none of the articles reported
individual difference scores.
Although all commercially available guinea pig colonies were
originally derived from one breeding colony (started by Dunkin
and Hartley in 1926, personal communication S. Ripke, Harlan
Laboratories, Venlo, Netherlands; see footnote), differences bet-
ween colonies are likely to develop over time. Strain differences in
anxiety behaviour and drug sensitivity are well documented for
rats and mice (Van Bogaert et al., 2006; Griebel et al., 2000), but
we are not aware of literature describing potential differences in
anxiety behaviour between guinea pig strains. Surprisingly, none
of the articles provided the ofﬁcial laboratory code of the strain
used. Most articles did report the supplier, but suppliers may
replace their colonies, in which case the generic name (e.g. Dunkin
Hartley from Harlan UK) is still current, but the actual strain may
well differ (see footnote). Therefore, it proved pointless to analyse
strain differences in this test.1
In rats and mice, perinatal stress exposure can have considerably
effects on anxiety behaviour (Sanchez et al., 2001). To the best of our
knowledge, such behavioural effects have not been studied in guinea
pigs. Available data indicate that test results obtained with pups
transported shortly after birth, does not differ from that of pups
obtained from transported pregnant dams. The data further suggest
that if pups were bred in a laboratory colony (low perinatal stress),
effect sizes were smaller, but this could not reliably be analysed.
Pettijohn (1979a) showed that vocalization behaviour remains
relatively stable over the ﬁrst four postnatal weeks, which is in line
with our ﬁnding that age has no effect on treatment efﬁcacy, although
this ﬁnding could be confounded with the factor repeated testing.
Though pups are still young when tested, sex differences could well
inﬂuence vocalization behaviour. Guinea pigs can reach sexual matur-
ity from four weeks of age (Trillmich et al., 2009), sex differences in
brain morphology may occur before puberty (Severi et al., 2005), and
prenatal stress may affect females differently than males (Schopper et
al., 2012; Bauer et al., 2008). However, data were insufﬁcient to assess
the effect of sex on treatment efﬁcacy.
Guinea pigs are communal animals, and vocalization among
group members is important in their social interactions. The vocal
repertoire of guinea pigs is highly developed: at least eleven
different types of calls have been identiﬁed (Berryman, 1976),
including whistles, purring and shrieking. The guinea pig pup
separation calls have been classiﬁed as “whistles”, which are
mainly audible sounds (Berryman, 1976), and probably serve as
contact call for maternal attention (Pettijohn, 1977). Acoustic
analysis comparing the ﬁrst thirty calls with the last thirty calls
within a 15 min isolation period, showed that whistle duration
decreases, and mean frequency increases over time (Monticelli
et al., 2004). Although initial studies speciﬁed the type of calls, it is
unclear to what extent these or other calls are measured in the
reported studies, since call characteristics are hardly reported.
In addition, the duration of a call may vary and change over
time (Monticelli et al., 2004), and drugs may alter call character-
istics, although this has hardly been studied (Wright et al., 2010).
As the total time spent on vocalization is independent of indivi-
dual call length, total duration of emitted calls may be a more
reliable outcome measure than total number of calls. The current
review however, indicates that with regard to sensitivity and
precision, both outcome measures are equally valid to evaluate
pharmacological interventions. Yet, since duration is a continuous
measure, it is generally more suited for analysis of variance, the
statistical method applied in most articles.
Test duration of a GPDV test is typically 5 min, although shorter
(2 min) and longer tests have also been performed (from 12 to
15 min; Table 3). The effect of test duration could not be analysed, but
the test periods used, are probably all within the optimal time
window of separation calls. Hennessy and co-workers showed that
vocalization behaviour markedly decreases and immobility levels
increase after 30 min of social isolation (Hennessy et al., 1997, 1991;
Hennessy and Moorman, 1989). In fact, studies using a considerable
longer test duration (Table 3, 30 min or more), studied mechanisms
1 Harlan UK (formerly known as OLAC) introduced the Dunkin Hartley strain in
1969 (laboratory code Ola:Dunkin Hartley), with animals derived from Porton.
Harlan UK replaced the Ola:Dunkin Hartley by HsdPoc:DH (Dunkin Hartley, derived
from Porcellus-animal-breeding-limited, Heathﬁeld, UK) in the early nineties. In
2013, Harlan UK (and Harlan Netherlands) started breeding the HsdDhl:DH outbred
strain (derived from David Hall and partners, UK). Charles River laboratories
introduced the strain in 1968; nomenclature Hartley (Crl:HA), obtained from the
Medical Research Council, UK.
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underlying the shift from active to passive coping behaviour during
prolonged social isolation (Hennessy et al., 2011a; Becker and
Hennessy, 1993; McInturf and Hennessy, 1996).
Guinea pigs are stress sensitive animals and environmental
stimuli may well affect their vocalization behaviour and sensitivity
to drugs. Presence of the mother in the test cage prevented the
actions of a CRF receptor antagonist on vocalization behaviour
(Hennessy et al., 1997; Pettijohn, 1979a), whereas presence of the
experimenter in the test room reduced overall vocalizations
(personal communication PM Verdouw). Likewise, testing in a
dimly lit room, in a closed cabinet, reduces the vocalization
response (Hennessy and Ritchey, 1987; Arch-Tirado et al., 2000),
as does repeatedly disrupting the litter within a short time
window (Arch-Tirado et al., 2000; Hennessy et al., 2006). Pre-
sently, reporting of these experimental details is poor and should
therefore be greatly improved.
4.3. Reporting of measures to reduce risk of bias and biases in
publication
The quality of included articles was low, and visual inspection
of the funnel plot indicated that neutral and negative studies are
probably underrepresented in our data set.
It is possible that most authors merely failed to report study
characteristics and measures to reduce bias, which are funda-
mental to good scientiﬁc practice, but there is reason for concern.
Several recent systematic reviews on experimental animal studies
have shown that methodological rigor is low in many ﬁelds of
preclinical research, which may lead to inﬂated treatment effects
(Sena et al., 2014). Together with the frequently observed risk of
publication bias (Sena et al., 2010; see also below) and the
difﬁculties in obtaining missing data from the authors, valuable
information is lost to the scientiﬁc community. This may result in
misconception of e.g. disease mechanisms and drug efﬁcacy, as
well as redundant animal studies and unnecessary duplications.
Although there is no guarantee that the translational value of
animal models will increase with improved conduct and reporting
of preclinical research, we strongly support the implementation of
publication guidelines such as the ARRIVE guidelines and the gold
standard publication checklist (GSPC), to optimize the information
provided in publications and to improve awareness regarding
study quality (Kilkenny et al., 2010; Hooijmans et al., 2011).
4.4. Strengths and limitations
We systematically and objectively quantiﬁed the effect of
pharmacological interventions in the guinea pig pup vocalization
test. We identiﬁed methodological factors that may improve test
sensitivity and reduce the number of animal needed.
It proved impossible to study the effect of individual drugs.
Categorizing drugs into classes may conceal particular characteristics
of a drug, relative to other drugs within its class. If indicated, we
performed sensitivity analysis to control for this. Also, no data were
available to actively control for potential muscular or sedative effects,
which may occur at higher doses and could interfere with vocaliza-
tion behaviour.
Finally, overall study quality was poor, which may have caused
an overestimation of drug efﬁcacy in the individual studies, as well
as in our meta-analysis.
4.5. Concluding remarks and recommendations
The separation-induced vocalization test in guinea pig seems
suited as global screen to detect potential anxiolytic drug properties.
There were however, insufﬁcient data to reliably determine pharma-
cological sensitivity and speciﬁcity of the test. Selecting pups with
moderate to high levels of vocalization and repeated testing of pups
are associated with larger treatment effects. Reporting of study
characteristics was poor, risk of bias high and there is possible pub-
lication bias present in this ﬁeld of research. We therefore urgently
call for proper conduct and reporting of experimental animals studies
in this ﬁeld, as well as publication of all available data. These
conditions are crucial to further our understanding of the transla-
tional value of animal models for anxiety disorders and the pharma-
cological treatment thereof.
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